Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and
VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.